Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis

Completed · Phase 1/Phase 2

Conditions studied: Systemic Sclerosis, Scleroderma

In brief

Systemic Sclerosis (also known as Scleroderma) is a chronic, autoimmune disease of the connective tissue generally classified as one of the rheumatic diseases. Systemic Sclerosis causes fibrosis (scar tissue) to be formed in the skin and internal organs. The fibrosis eventually causes the involved skin to harden, limiting mobility, and can also damage other organs. Excess Transforming Growth Factor Beta-1 (TGF-beta1) activity may result in the abnormal fibrosis characteristic of Systemic Sclerosis. An antibody against TGF-beta1 may modify pathologic processes characterized by inappropriate fibrosis. Genzyme Corporation is currently investigating a human monoclonal antibody (CAT-192) that neutralizes active TGF-beta1. This study is being conducted in the U.S. and Europe to evaluate the safety, tolerability, and pharmacokinetics of repeated treatments with CAT-192 in patients with early stage diffuse Systemic Sclerosis.

Key facts

Study ID

NCT00043706

Run by

Genzyme, a Sanofi Company

Expected to finish

2003-09-01

Last updated by the study team

2015-03-05

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of diffuse systemic sclerosis
• Duration of disease 18 months or less
• Modified Rodnan Skin Score in a range as identified by the study protocol
• Evidence of worsening disease activity
• Ability to attend follow-up assessments for a minimum of 9 months
• Agree to delay elective surgery during the trial and up to 9 months after final infusion
• Agree to delay reproduction during the trial and up to 9 months after final infusion

You may not qualify if…

• Women who are pregnant or lactating
• Clinical evidence of other definable connective tissue or autoimmune disease
• Severe kidney, heart, lung, or gastrointestinal disease
• Treatment with protocol-specified immunosuppressants within 4 weeks of starting the clinical study
• Treatment with systemic corticosteroids in a dose greater than 10 mg/day of prednisone or equivalent (inhaled steroids at standard doses are allowed)
• Current treatment by photopheresis

Where it is running

• UCLA-Department of Medicine, Division of Rheumatology — Los Angeles, California, United States
• Boston Medical Center — Boston, Massachusetts, United States
• UMDNJ Scleroderma Program — New Brunswick, New Jersey, United States
• University of Texas - Houston Medical School — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.